Why the study?
Do medical treatments (beta-blockers, ACE inhibitors, aspirin, anticoagulants, cardiac rehabilitation, lipid management) reduce cardiovascular morbidity and mortality in patients after myocardial infarction?
Do medical treatments (beta-blockers, ACE inhibitors, aspirin, anticoagulants, cardiac rehabilitation, lipid management) reduce cardiovascular morbidity and mortality in patients after myocardial infarction?
Multiple medical therapies including beta-blockers, ACE inhibitors, aspirin, and lipid management are beneficial for secondary prevention in post-myocardial infarction patients.
Supports secondary prevention post-MI; leaves open optimization questions for contemporary trials.
Patients who have had myocardial infarction and are at risk for continued problems may benefit from several treatment methods (table 1). Beta-adrenergic blockers reduce subsequent cardiovascular morbidity and mortality through their effect on the myocardial supply-demand balance. Administration of angiotensin-converting enzyme inhibitors reduces morbidity and mortality rates in myocardial infarction survivors who have diminished left ventricular ejection fraction. Aspirin and other anticoagulants are beneficial through their antiplatelet effects. Cardiac rehabilitation methods and aggressive management of lipids levels are also useful.
No takes yet. Share an insight, caveat, or question.
Lucy Smith (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: